)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bio-Works Technologies
Bio-Works Technologies (BIOWKS) investor relations material
Bio-Works Technologies Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Nine-month net sales rose 52% YoY to 59.0 MSEK and operating loss narrowed to 7.0 MSEK; Q3 sales and earnings weakened as deliveries declined.
Q3 order intake increased to 40.8 MSEK from 10.0 MSEK, with several orders scheduled for delivery in future periods.
Financial highlights
Q3 net sales were 9.6 MSEK vs 16.6 MSEK; operating loss was 8.1 MSEK vs 1.2 MSEK, and net loss was 7.7 MSEK vs 1.4 MSEK.
9M net sales were 59.0 MSEK vs 38.8 MSEK; operating loss was 7.0 MSEK vs 16.6 MSEK, and net loss was 5.5 MSEK vs 16.6 MSEK.
9M order intake was 65.3 MSEK vs 68.9 MSEK; Q3 intake reached 40.8 MSEK vs 10.0 MSEK.
Q3 personnel and other external costs totaled 15.4 MSEK vs 13.6 MSEK; 9M total was 50.6 MSEK vs 44.4 MSEK.
Outlook and guidance
Several Q3 orders are scheduled for delivery from Q4 2026 through Q4 2027; order-to-delivery timing can make quarterly sales and earnings uneven.
Priorities include converting customer interest and secured orders into completed projects, revenue and a more stable business, with greater emphasis on commercial efficiency.
Operations were assessed as financed for at least the next 12 months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bio-Works Technologies
- Strong sales growth and improved profitability, with new CEO announced for November.BIOWKS
Q2 2026 - Strong sales growth and profitability turnaround, with improved cash flow and equity.BIOWKSQ1 2026
- Record sales, improved profit, and strong order intake mark a breakthrough year.BIOWKSQ4 2025
- Q3 2025 saw 70% sales growth, improved margins, and key strategic advances.BIOWKSQ3 2025
- Q2 2025 saw 86% sales growth, strong orders, and improved operating results, led by Europe.BIOWKSQ2 2025
- Order intake up 16% and net loss narrowed, with financing secured for the next 12 months.BIOWKSQ2 2024
- Q3 sales surged 44% and losses narrowed, with liquidity boosted by an oversubscribed rights issue.BIOWKSQ3 2024
- Record Q1 order intake and improved margins signal strong momentum for Bio-Works in 2025.BIOWKSQ1 2025
- Cost controls narrowed losses despite lower sales; large new orders boost 2025 outlook.BIOWKSQ4 2024
Next Bio-Works Technologies earnings date
Q4 202619 Feb, 2027
Bio-Works Technologies
Next Bio-Works Technologies earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bio-Works Technologies is a Sweden-based biotechnology company that develops and manufactures products used in bioseparation and purification processes. Its offerings include resins and chromatography materials for use in laboratory research, diagnostics, and biopharmaceutical manufacturing. The company serves customers in academic, industrial, and pharmaceutical sectors. Bio-Works Technologies is headquartered in Uppsala, Sweden, and its shares are listed on the NASDAQ Stockholm.